NASDAQ$KLRS
Kalaris Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
AlloVir reported financial results for the third quarter ended September 30, 2022 and shared progress across its allogeneic T cell programs.
AlloVir reported a net loss of $42.1 million, or $0.50 per share, for the third quarter ended September 30, 2022. The company's research and development expenses were $30.0 million, and general and administrative expenses were $12.9 million. As of September 30, 2022, AlloVir had cash, cash equivalents, and marketable securities of $264.1 million.
- Posoleucel continues to advance in three ongoing multi-national Phase 3 registrational trials.
- Final data presentation from Posoleucel Phase 2 multi-virus prevention study by year-end.
- Final topline data from Posoleucel Phase 2 study for treatment of BK Viremia in kidney transplant patients on track to be released in Q1 2023.
- AlloVir plans to host an investor webcast on December 14 to discuss the unmet medical need for and clinical value of a multi-virus prevention approach in the management of allo-HCT patients.
Headline financials
Revenue & EPS history
Allovir · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.5%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+5.9%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+33.6%
Q2 2022
Best reaction
-23.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -1.8% | +6.9% | +75.0% | |
| Q2 2025 | -10.9% | +0.4% | +56.2% | |
| Q2 2024 | -3.3% | -5.7% | +75.0% | |
| Q1 2025 | -6.1% | -2.8% | +5.6% | |
| Q4 2025 | -3.4% | +4.2% | -21.2% | |
| Q3 2024 | -23.8% | -23.0% | -37.8% | |
| Q1 2024 | -1.7% | -1.4% | +0.5% | |
| Q4 2023 | +0.7% | +2.5% | +5.5% | |
| Q3 2023 | +9.1% | +9.1% | +27.9% | |
| Q2 2023 | +3.0% | +0.3% | +6.6% | |
| Q1 2023 | +14.2% | +13.0% | +2.6% | |
| Q4 2022 | -6.1% | +5.5% | -30.9% | |
| Q3 2022 | +0.9% | +9.1% | +10.5% | |
| Q2 2022 | +33.6% | +37.7% | +31.7% | |
| Q1 2022 | +0.4% | -23.8% | -25.3% | |
| Q4 2021 | +2.3% | +3.6% | -14.1% | |
| Q3 2021 | -2.3% | -3.0% | -28.9% | |
| Q2 2021 | +6.1% | +0.6% | +0.0% | |
| Q1 2021 | +9.7% | +5.0% | +6.0% | |
| Q4 2020 | +0.5% | -2.5% | -29.4% | |
| Q3 2020 | -0.5% | -6.3% | +24.2% | |
| Q2 2020 | -9.7% | -20.6% | -9.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro